Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stada Claims A First With Ready-To-Use Bortezomib In Europe

Executive Summary

Stada says it is not only first-to-market with generic bortezomib in major European markets. It is also offering a more convenient ready-to-use solution.

You may also be interested in...



Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings

Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.

Revlimid Rivals Launch Across Europe

Generic versions of Revlimid have been launched in countries across Europe, with Sandoz and Stada among those to have confirmed the introduction of lenalidomide in numerous European markets. Meanwhile, US competition to Revlimid is expected next month.

Stada Launches Bevacizumab Biosimilar In EU

Stada has launched its Oyavas version of bevacizumab upon EU approval, initially rolling out the oncology biosimilar in Germany and the Netherlands with other countries to follow.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel